USA Pharma News | Healthcare News

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

Badari Andukuri

4 days ago

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

Badari Andukuri

Jan 31

Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter

Badari Andukuri

Jan 26

FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter

Badari Andukuri

Jan 23

Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter

ipharmaservices

Jan 22

Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma

ipharmaservices

Jan 17

Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases

Badari Andukuri

Dec 23, 2025

FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management

ipharmaservices

Dec 23, 2025

FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

Badari Andukuri

Dec 5, 2025

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

ipharmaservices

Dec 4, 2025

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

ipharmaservices

Dec 4, 2025

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

ipharmaservices

Dec 2, 2025

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

Badari Andukuri

Dec 2, 2025

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

Badari Andukuri

Dec 1, 2025

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

ipharmaservices

Nov 23, 2025

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Nov 19, 2025

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

ipharmaservices

Feb 3, 2025

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

ipharmaservices

Jan 3, 2025

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

ipharmaservices

Apr 3, 2024

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

ipharmaservices

Mar 28, 2024